Previous 10 | Next 10 |
– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death – – Vir and GSK plan to immediately seek Emergency Use Authorization in the U.S. and authorizations in other countries ...
Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet. In this video from Motle...
Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by ...
Shares of Vir Biotechnology (NASDAQ: VIR) are dropping sharply on Thursday despite the drugmaker not reporting any news. We can probably attribute the stock's decline to a Wall Street analyst deciding to lower his price target on Vir Biotechnology. As of 12:23 p.m. EST, shares of th...
Shares of Vir Biotechnology, Inc. (VIR) have continued the slide that began before the opening bell, down 26.7% to $42.35 in late afternoon trading.This morning, Vir announced that a data and safety monitoring board recommended that the VIR-7831 arm of the ACTIV-3 phase 3 study in C...
Shares of Vir Biotechnology (NASDAQ: VIR) are plunging on Wednesday following the company's release of an update regarding one of its leading pipeline candidates. At 12:28 p.m. EST the drugmaker's stock was down by 33% after falling by as much as 35.3% earlier in the day. Vir Bi...
Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceutica...
Vir Biotechnology (VIR), down 17% premarket and GlaxoSmithKline (GSK) provide an update on the VIR-7831 (GSK4182136) arm of the Accelerating COVID-19 Therapeutic Interventions and Vaccines ((ACTIV)) Program Phase 3 clinical trial.While VIR-7831 met initial pre-specified criteri...
SAN FRANCISCO and LONDON, March 03, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Int...
Vir Biotechnology's (VIR) Q4 2020 results missed analyst expectations on both EPS and revenue.Revenues rose to $1.7M from $1M in the prior-year period.The company's net loss widened to $105.6M from $63.8M.R&D expenses rose to $87.1M compared to $52.9M in Q4 2019.In the pipeline, Vir says ...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...